Literature DB >> 20881005

Acetylcholine receptor (AChR) α5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (α4β2)₂α5 AChR function.

Alexander Kuryatov1, Wade Berrettini, Jon Lindstrom.   

Abstract

Genomic studies have identified a D398N variation in the α5 subunit of nicotinic acetylcholine receptors (AChRs) that increases risk of nicotine dependence and lung cancer. (α4β2)₂α5 AChRs are a significant brain presynaptic subtype in brain. Their high sensitivity to activation by nicotine and high Ca²+ permeability give them substantial functional impact. α3β4* and α3β2* AChRs are predominant postsynaptic AChRs in the autonomic nervous system, but rare in brain. The amino acid 398 of α5 is located in the large cytoplasmic domain near the amphipathic α helix preceding the M4 transmembrane domain. These helices have been shown to influence AChR conductance by forming portals to the central channel. We report that α5 Asn 398 lowers Ca²+ permeability and increases short-term desensitization in (α4β2)₂α5 but not in (α3β4)₂α5 or (α3β2)₂α5 AChRs. This suggests that a positive allosteric modulator would augment nicotine replacement therapy for those with this risk variant. α5 D398N variation does not alter sensitivity to activation. The high sensitivity to activation and desensitization of (α4β2)₂α5 AChRs by nicotine results in a narrow concentration range in which activation and desensitization curves overlap. This region centers on 0.2 μM nicotine, a concentration typically sustained in smokers. This concentration would desensitize 60% of these AChRs and permit smoldering activation of the remainder. The low sensitivity to activation and desensitization of (α3β4)₂α5 AChRs by nicotine results in a broad region of overlap centered near 10 μM. Thus, at the nicotine concentrations in smokers, negligible activation or desensitization of this subtype would occur.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20881005      PMCID: PMC3014277          DOI: 10.1124/mol.110.066357

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  36 in total

1.  Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor.

Authors:  W Xu; S Gelber; A Orr-Urtreger; D Armstrong; R A Lewis; C N Ou; J Patrick; L Role; M De Biasi; A L Beaudet
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

2.  A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization.

Authors:  Raymond S Hurst; Mihaly Hajós; Mario Raggenbass; Theron M Wall; Nicole R Higdon; Judy A Lawson; Karen L Rutherford-Root; Mitchell B Berkenpas; W E Hoffmann; David W Piotrowski; Vincent E Groppi; Geraldine Allaman; Roch Ogier; Sonia Bertrand; Daniel Bertrand; Stephen P Arneric
Journal:  J Neurosci       Date:  2005-04-27       Impact factor: 6.167

3.  Common determinants of single channel conductance within the large cytoplasmic loop of 5-hydroxytryptamine type 3 and alpha4beta2 nicotinic acetylcholine receptors.

Authors:  Tim G Hales; James I Dunlop; Tarek Z Deeb; Jane E Carland; Stephen P Kelley; Jeremy J Lambert; John A Peters
Journal:  J Biol Chem       Date:  2006-01-03       Impact factor: 5.157

Review 4.  Pharmacology of nicotine: addiction and therapeutics.

Authors:  N L Benowitz
Journal:  Annu Rev Pharmacol Toxicol       Date:  1996       Impact factor: 13.820

5.  Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors.

Authors:  A Kuryatov; J Luo; J Cooper; J Lindstrom
Journal:  Mol Pharmacol       Date:  2005-09-23       Impact factor: 4.436

6.  Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors.

Authors:  L Tapia; A Kuryatov; J Lindstrom
Journal:  Mol Pharmacol       Date:  2006-11-28       Impact factor: 4.436

7.  First and second transmembrane segments of alpha3, alpha4, beta2, and beta4 nicotinic acetylcholine receptor subunits influence the efficacy and potency of nicotine.

Authors:  Ray Rush; Alexander Kuryatov; Mark E Nelson; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2002-06       Impact factor: 4.436

8.  Chronic nicotine treatment up-regulates human alpha3 beta2 but not alpha3 beta4 acetylcholine receptors stably transfected in human embryonic kidney cells.

Authors:  F Wang; M E Nelson; A Kuryatov; F Olale; J Cooper; K Keyser; J Lindstrom
Journal:  J Biol Chem       Date:  1998-10-30       Impact factor: 5.157

9.  alpha 5 Subunit alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of human neuronal alpha 3 nicotinic receptors.

Authors:  V Gerzanich; F Wang; A Kuryatov; J Lindstrom
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

10.  Human alpha4beta2 acetylcholine receptors formed from linked subunits.

Authors:  Yan Zhou; Mark E Nelson; Alexander Kuryatov; Catherine Choi; John Cooper; Jon Lindstrom
Journal:  J Neurosci       Date:  2003-10-08       Impact factor: 6.167

View more
  110 in total

1.  Plasticity of prefrontal attention circuitry: upregulated muscarinic excitability in response to decreased nicotinic signaling following deletion of α5 or β2 subunits.

Authors:  Michael K Tian; Craig D C Bailey; Mariella De Biasi; Marina R Picciotto; Evelyn K Lambe
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

2.  Rare missense variants in CHRNB4 are associated with reduced risk of nicotine dependence.

Authors:  Gabe Haller; Todd Druley; Francesco L Vallania; Robi D Mitra; Ping Li; Gustav Akk; Joe Henry Steinbach; Naomi Breslau; Eric Johnson; Dorothy Hatsukami; Jerry Stitzel; Laura J Bierut; Alison M Goate
Journal:  Hum Mol Genet       Date:  2011-10-31       Impact factor: 6.150

3.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

4.  Cotinine conundrum--a step forward but questions remain.

Authors:  Margaret R Spitz; Christopher I Amos; Laura J Bierut; Neil E Caporaso
Journal:  J Natl Cancer Inst       Date:  2012-04-25       Impact factor: 13.506

5.  Function of human α3β4α5 nicotinic acetylcholine receptors is reduced by the α5(D398N) variant.

Authors:  Andrew A George; Linda M Lucero; M Imad Damaj; Ronald J Lukas; Xiangning Chen; Paul Whiteaker
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

6.  Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers.

Authors:  Alexandre Kuryatov; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2010-10-05       Impact factor: 4.436

7.  Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.

Authors:  Li-Shiun Chen; Timothy B Baker; Megan E Piper; Naomi Breslau; Dale S Cannon; Kimberly F Doheny; Stephanie M Gogarten; Eric O Johnson; Nancy L Saccone; Jen C Wang; Robert B Weiss; Alison M Goate; Laura Jean Bierut
Journal:  Am J Psychiatry       Date:  2012-07       Impact factor: 18.112

8.  The genetic basis of addictive disorders.

Authors:  Francesca Ducci; David Goldman
Journal:  Psychiatr Clin North Am       Date:  2012-06

9.  Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.

Authors:  Kazuko Sakata; Abigail E Overacre
Journal:  J Neurochem       Date:  2017-08-16       Impact factor: 5.372

10.  Crucial role of nicotinic α5 subunit variants for Ca2+ fluxes in ventral midbrain neurons.

Authors:  Miriam Sciaccaluga; Claudia Moriconi; Katiuscia Martinello; Myriam Catalano; Isabel Bermudez; Jerry A Stitzel; Uwe Maskos; Sergio Fucile
Journal:  FASEB J       Date:  2015-04-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.